外文期刊订阅>期刊> Clinical Cancer Research

(被订阅21次)

  出版社: The Association
  期刊类型: 半月刊
  影响因子: 7.338(2010年)
  ISSN: 1078-0432
  所在领域: 生命科学   
 
 

Clinical Cancer Research publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its fo...

展开

Clinical Cancer Research publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome, and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

收缩

 

Clinical Cancer Research

中文名: 临床癌症研究  缩写名: Clin Cancer Res

收入刊期 2012年   2011年   2010年   2009年   2008年  

最新期2012年18-8期内容

1 First Evidence That gamma-Tocotrienol Inhibits the Growth of Human Gastric Cancer and Chemosensitizes It to Capecitabine in a Xenograft Mouse Model through the Modulation of NF-kappa B Pathway
2 The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin
3 Improved Efficacy of Dendritic Cell-Based Immunotherapy by Cutaneous Laser Illumination
4 Cytokine BAFF Gene Variation Is Associated with Survival of Patients with T-cell Lymphomas
5 Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
6 cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes
7 Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma
8 Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
9 The Use and Interpretation of Competing Risks Regression Models
10 Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints
11 The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
12 BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency
13 A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
14 A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
15 Whole Blood Stem Cell Reinfusion and Escalated Dose Melphalan in Castration-Resistant Prostate Cancer: A Phase 1 Study
更多
本刊文章检索  
  文章名  
  作者  
  摘要